Longeveron (LGVN) Consolidated Net Income (2020 - 2026)
Longeveron's (LGVN) quarterly Consolidated Net Income came in at -$5.5 million in Q1 2026, up 14.64% year-on-year from -$4.8 million in Q1 2025, and up 11.31% quarter-over-quarter from -$6.3 million in Q4 2025.
Longeveron (LGVN) Consolidated Net Income (2020 - 2026) Analysis & Trends
Longeveron's Consolidated Net Income history runs 7 years deep, the most recent figure standing at -$5.5 million for Q1 2026.
- On a quarterly basis, Consolidated Net Income rose 14.64% year-over-year to -$5.5 million in Q1 2026; TTM through Mar 2026 was -$27.4 million, a 35.82% decrease from a year earlier, with the FY2025 full-year figure at -$24.3 million, up 29.52% from the prior year.
- Consolidated Net Income improved to -$5.5 million in Q1 2026 per LGVN's latest filing, from -$6.3 million in the prior quarter.
- Across five years, Consolidated Net Income topped out at -$3.5 million in Q2 2024 and bottomed at -$42.7 million in Q1 2023.
- The 5-year median for Consolidated Net Income is -$5.4 million (2022), against an average of -$7.7 million.
- Across the five-year window, Consolidated Net Income plunged 942.87% in 2023 and soared 89.9% in 2024, its largest moves.
- Year by year, Consolidated Net Income stood at -$5.2 million in 2022, then slipped by 4.63% to -$5.5 million in 2023, then increased by 4.11% to -$5.2 million in 2024, then declined by 19.18% to -$6.3 million in 2025, then rose by 11.31% to -$5.5 million in 2026.
- Per Business Quant, the three latest LGVN Consolidated Net Income figures stand at -$5.5 million (Q1 2026), -$6.3 million (Q4 2025), and -$8.8 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Longeveron | 14.87 Bn | 14.86 Bn | 264,000.00 | -5.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5.55 Mn |
| Dec 31, 2025 | -6.25 Mn |
| Sep 30, 2025 | -8.78 Mn |
| Jun 30, 2025 | -6.81 Mn |
| Mar 31, 2025 | -6.50 Mn |
| Dec 31, 2024 | -5.25 Mn |
| Sep 30, 2024 | -4.87 Mn |
| Jun 30, 2024 | -3.55 Mn |
| Mar 31, 2024 | -4.31 Mn |
| Dec 31, 2023 | -5.47 Mn |
| Sep 30, 2023 | -5.39 Mn |
| Jun 30, 2023 | -5.95 Mn |
| Mar 31, 2023 | -42.72 Mn |
| Dec 31, 2022 | -5.23 Mn |
| Sep 30, 2022 | -5.41 Mn |
| Jun 30, 2022 | -4.92 Mn |
| Mar 31, 2022 | -4.10 Mn |
| Dec 31, 2021 | 44.90 Mn |
| Sep 30, 2021 | -22.91 Mn |
| Jun 30, 2021 | -20.06 Mn |